Clinical significance of loss of Fhl1 expression in human gastric cancer

Katsuya Sakashita, Koshi Mimori, Fumiaki Tanaka, Yukio Kamohara, Hiroshi Inoue, Tetsuji Sawada, Kosei Hirakawa, Masaki Mori

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Human four-and-a-half LIM domains 1 (Fhl1) gene has been reported to achieve cancer suppressive effects. The purpose of this study is to clarify clinical significance of Fhl1 expression in gastric cancer. Methods: Fhl1 mRNA expression was quantified by real-time reverse transcription (RT)-polymerase chain reaction (PCR) using paired tumor and normal clinical samples from a total of 110 gastric cancer patients. Fhl1 protein expression was investigated by immunohistochemistry. The relationship between Fhl1 mRNA expression and clinicopathological factors was statistically analyzed. Results: Fhl1 mRNA expression in tumor tissue was significantly downregulated compared with that in normal mucosa (P < 0.0001). Fhl1 protein expression was also diminished in cancer cells by immunohistochemistry. Kaplan-Meier survival curves demonstrated that the patients with low Fhl1 expression tumor showed significantly shorter survival (P < 0.05) than those with high Fhl1 expression tumor. Furthermore, the tumors with low Fhl1 expression showed deeper invasion into the serosal layer (P < 0.05) or more frequent distant metastasis (P < 0.01). Conclusion: Fhl1 gene was underexpressed in clinical gastric cancer. Loss of Fhl1 expression would be a novel biomarker to determine biological aggressiveness of gastric cancer.

Original languageEnglish
Pages (from-to)2293-2300
Number of pages8
JournalAnnals of Surgical Oncology
Volume15
Issue number8
DOIs
Publication statusPublished - Aug 1 2008

Fingerprint

Stomach Neoplasms
Neoplasms
Messenger RNA
Immunohistochemistry
Kaplan-Meier Estimate
Genes
Reverse Transcription
Mucous Membrane
Proteins
Down-Regulation
Biomarkers
Neoplasm Metastasis
Polymerase Chain Reaction
Survival

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Clinical significance of loss of Fhl1 expression in human gastric cancer. / Sakashita, Katsuya; Mimori, Koshi; Tanaka, Fumiaki; Kamohara, Yukio; Inoue, Hiroshi; Sawada, Tetsuji; Hirakawa, Kosei; Mori, Masaki.

In: Annals of Surgical Oncology, Vol. 15, No. 8, 01.08.2008, p. 2293-2300.

Research output: Contribution to journalArticle

Sakashita, K, Mimori, K, Tanaka, F, Kamohara, Y, Inoue, H, Sawada, T, Hirakawa, K & Mori, M 2008, 'Clinical significance of loss of Fhl1 expression in human gastric cancer', Annals of Surgical Oncology, vol. 15, no. 8, pp. 2293-2300. https://doi.org/10.1245/s10434-008-9904-3
Sakashita, Katsuya ; Mimori, Koshi ; Tanaka, Fumiaki ; Kamohara, Yukio ; Inoue, Hiroshi ; Sawada, Tetsuji ; Hirakawa, Kosei ; Mori, Masaki. / Clinical significance of loss of Fhl1 expression in human gastric cancer. In: Annals of Surgical Oncology. 2008 ; Vol. 15, No. 8. pp. 2293-2300.
@article{fbfc5e63bdf041baa80d863f9f051cc9,
title = "Clinical significance of loss of Fhl1 expression in human gastric cancer",
abstract = "Background: Human four-and-a-half LIM domains 1 (Fhl1) gene has been reported to achieve cancer suppressive effects. The purpose of this study is to clarify clinical significance of Fhl1 expression in gastric cancer. Methods: Fhl1 mRNA expression was quantified by real-time reverse transcription (RT)-polymerase chain reaction (PCR) using paired tumor and normal clinical samples from a total of 110 gastric cancer patients. Fhl1 protein expression was investigated by immunohistochemistry. The relationship between Fhl1 mRNA expression and clinicopathological factors was statistically analyzed. Results: Fhl1 mRNA expression in tumor tissue was significantly downregulated compared with that in normal mucosa (P < 0.0001). Fhl1 protein expression was also diminished in cancer cells by immunohistochemistry. Kaplan-Meier survival curves demonstrated that the patients with low Fhl1 expression tumor showed significantly shorter survival (P < 0.05) than those with high Fhl1 expression tumor. Furthermore, the tumors with low Fhl1 expression showed deeper invasion into the serosal layer (P < 0.05) or more frequent distant metastasis (P < 0.01). Conclusion: Fhl1 gene was underexpressed in clinical gastric cancer. Loss of Fhl1 expression would be a novel biomarker to determine biological aggressiveness of gastric cancer.",
author = "Katsuya Sakashita and Koshi Mimori and Fumiaki Tanaka and Yukio Kamohara and Hiroshi Inoue and Tetsuji Sawada and Kosei Hirakawa and Masaki Mori",
year = "2008",
month = "8",
day = "1",
doi = "10.1245/s10434-008-9904-3",
language = "English",
volume = "15",
pages = "2293--2300",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - Clinical significance of loss of Fhl1 expression in human gastric cancer

AU - Sakashita, Katsuya

AU - Mimori, Koshi

AU - Tanaka, Fumiaki

AU - Kamohara, Yukio

AU - Inoue, Hiroshi

AU - Sawada, Tetsuji

AU - Hirakawa, Kosei

AU - Mori, Masaki

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Background: Human four-and-a-half LIM domains 1 (Fhl1) gene has been reported to achieve cancer suppressive effects. The purpose of this study is to clarify clinical significance of Fhl1 expression in gastric cancer. Methods: Fhl1 mRNA expression was quantified by real-time reverse transcription (RT)-polymerase chain reaction (PCR) using paired tumor and normal clinical samples from a total of 110 gastric cancer patients. Fhl1 protein expression was investigated by immunohistochemistry. The relationship between Fhl1 mRNA expression and clinicopathological factors was statistically analyzed. Results: Fhl1 mRNA expression in tumor tissue was significantly downregulated compared with that in normal mucosa (P < 0.0001). Fhl1 protein expression was also diminished in cancer cells by immunohistochemistry. Kaplan-Meier survival curves demonstrated that the patients with low Fhl1 expression tumor showed significantly shorter survival (P < 0.05) than those with high Fhl1 expression tumor. Furthermore, the tumors with low Fhl1 expression showed deeper invasion into the serosal layer (P < 0.05) or more frequent distant metastasis (P < 0.01). Conclusion: Fhl1 gene was underexpressed in clinical gastric cancer. Loss of Fhl1 expression would be a novel biomarker to determine biological aggressiveness of gastric cancer.

AB - Background: Human four-and-a-half LIM domains 1 (Fhl1) gene has been reported to achieve cancer suppressive effects. The purpose of this study is to clarify clinical significance of Fhl1 expression in gastric cancer. Methods: Fhl1 mRNA expression was quantified by real-time reverse transcription (RT)-polymerase chain reaction (PCR) using paired tumor and normal clinical samples from a total of 110 gastric cancer patients. Fhl1 protein expression was investigated by immunohistochemistry. The relationship between Fhl1 mRNA expression and clinicopathological factors was statistically analyzed. Results: Fhl1 mRNA expression in tumor tissue was significantly downregulated compared with that in normal mucosa (P < 0.0001). Fhl1 protein expression was also diminished in cancer cells by immunohistochemistry. Kaplan-Meier survival curves demonstrated that the patients with low Fhl1 expression tumor showed significantly shorter survival (P < 0.05) than those with high Fhl1 expression tumor. Furthermore, the tumors with low Fhl1 expression showed deeper invasion into the serosal layer (P < 0.05) or more frequent distant metastasis (P < 0.01). Conclusion: Fhl1 gene was underexpressed in clinical gastric cancer. Loss of Fhl1 expression would be a novel biomarker to determine biological aggressiveness of gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=48149086734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48149086734&partnerID=8YFLogxK

U2 - 10.1245/s10434-008-9904-3

DO - 10.1245/s10434-008-9904-3

M3 - Article

VL - 15

SP - 2293

EP - 2300

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 8

ER -